Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2025-03-31EMA Authorised: Giotrif (afatinib) — Boehringer Ingelheim International GmbH
EMA authorised Giotrif (afatinib) for non-small cell lung cancer, decision date 31 March 2025.
-
CLINICAL_TRIALS research · 2025-03-31Clinical Trial Update: SERS-Based Serum Molecular Spectral Screening for Lung Cancer Type
The document reports a not-yet-recruiting clinical trial evaluating a SERS-based serum spectral screening method for lung cancer type differ…
-
CLINICAL_TRIALS research · 2025-03-31Clinical Trial Update: Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors [NA]
Clinical trial investigating molecular imaging of FAP-expressing cancer-associated fibroblasts in non-small cell lung cancer patients treate…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] [Phase 3]
A Phase 3 study (IMpower010) evaluating atezolizumab versus best supportive care after chemotherapy in non-small cell lung cancer has posted…
-
CLINICAL_TRIALS research · 2025-03-30Clinical Trial Update: A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via Intraventricular Injection for the Treatment of Refractory Non-squamous Non-small Cell Lung Cancer with Leptomeningeal Metastases [Phase 2]
A Phase 2 trial is evaluating intraventricular pemetrexed plus nivolumab for refractory non-squamous non-small cell lung cancer with leptome…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors [Phase 1, Phase 2]
This clinical trial update describes evaluation of the PET tracer [18F]AlF-NOTA-PCP2 for PD-L1 detection across malignant tumors, including …
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
A Pfizer-sponsored study in Norway evaluating the effectiveness of cancer medicines in patients with metastatic non-small cell lung cancer h…
-
CLINICAL_TRIALS research · 2025-03-30Clinical Trial Update: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
This clinical trial update describes the validation and benchmarking of top-performing ctDNA diagnostic tests for stage III non-small cell l…
-
CLINICAL_TRIALS trial_result · 2025-03-28Clinical Trial Update: Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors [Phase 2]
Phase 2 study evaluating upfront afatinib with concurrent chemotherapy followed by osimertinib with concurrent chemotherapy in untreated EGF…
-
CLINICAL_TRIALS research · 2025-03-28Clinical Trial Update: [18F]F-AraG PET Imaging to Visualize Tumor Infiltrating T-cell Activation in Non-small Cell Lung Cancer. [NA]
A clinical trial update notes imaging with the tracer [18F]F-AraG to visualize tumor-infiltrating T-cell activation in non-small cell lung c…
-
CLINICAL_TRIALS research · 2025-03-28Clinical Trial Update: Long-term Follow-up of Checkpoint Inhibitors-induced Ileo-colitis
A clinical trial update describing long-term follow-up of immune checkpoint inhibitor–induced ileocolitis and ongoing recruitment for patien…
-
CLINICAL_TRIALS research · 2025-03-28Clinical Trial Update: A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer [NA]
A clinical imaging study evaluating changes in [18F]F-AraG uptake after anti-PD-1 therapy in advanced non-small cell lung cancer. The study …
-
CLINICAL_TRIALS research · 2025-03-28Clinical Trial Update: Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment [NA]
An ongoing clinical trial evaluating chest lymph node sampling in patients with advanced non-small cell lung cancer who are to receive curat…
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating alectinib for pretreatment RET-rearranged advanced non-small cell lung cancer has been terminated; results have bee…
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer [Phase 1]
Phase 1 study of RGX-104 in patients with advanced lung and endometrial cancer has completed.
-
CLINICAL_TRIALS trial_result · 2025-03-26Clinical Trial Update: Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC [Phase 2]
Phase II neoadjuvant and adjuvant trial of capmatinib in non-small cell lung cancer was terminated, with results posted on 2025-03-26.
-
CLINICAL_TRIALS research · 2025-03-26Clinical Trial Update: A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies [Phase 1, Phase 2]
An ongoing Phase 1/2 clinical trial evaluating AP203 in patients with locally advanced or metastatic solid tumors, including non-small cell …
-
CLINICAL_TRIALS research · 2025-03-26Clinical Trial Update: Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer
Clinical trial update describing a liquid biopsy assay using EBUS-TBNA supernatant fluid to diagnose lung cancer, currently recruiting.
-
CLINICAL_TRIALS research · 2025-03-26Clinical Trial Update: Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer [Phase 1, Phase 2]
This clinical trial update outlines a Phase 1/2 study of cisplatin delivered as a dry powder inhalation in patients with Stage IV non-small …
-
CLINICAL_TRIALS safety_alert · 2025-03-25Clinical Trial Update: Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases
A completed clinical trial update evaluating pulmonary physiology and systemic inflammatory responses associated with brigatinib use in non-…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer [Phase 1, Phase 2]
This update reports results from a Phase I/II trial of a triple-drug combination (nivolumab, ipilimumab, and nintedanib) for non-small cell …
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC [Phase 4]
Phase 4 trial update evaluating afatinib followed by osimertinib versus osimertinib alone in EGFR-mutated, T790M mutation-negative non-squam…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA [Phase 2]
A phase 2 trial of Tusamitamab ravtansine in non-small cell lung cancer patients with low to moderate CEACAM5 expression and high circulatin…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) [Phase 1]
Fortitude-201 (bemarituzumab) is a Phase 1 trial evaluating bemarituzumab alone or in combination with other anti-cancer therapies in FGFR2b…
-
CLINICAL_TRIALS research · 2025-03-25Clinical Trial Update: Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics [Phase 4]
This clinical trial registry entry outlines a Phase 4 study investigating mechanisms of resistance to lorlatinib induction therapy in resect…